It's been my understanding that many teaching hospitals that host trials provide their own PI along with other trial services. That's one scenerio.
Message in reply to:
Thanks for the nice summary, and hope you don't mind expression of two minor points of disagreement. First, the antiviral MOAs are all theoretical at this point, until we see some studies showing how brilacidin was able to reduce viral replication in vitro. Second, Regeneron's antibodies as you described are neutralizing antibodies, which bind to virus and make sure the body disposes of it before infecting cells. They are not immune-suppressing antibodies like used for many other diseases (and some of which were tried and failed in Covid-19: the anti-IL6 ones, which are somewhat immunosuppressive). They would not be much different than neutralizing antibodies induced naturally or by vaccine in that sense. They have a good chance of working prophylactically and early in the virological stage of disease. They have government backing so will be given the green light all the way.
Similarly, with proven safety of B-IV in ABSSSI and strong preclinical in vitro results, brilacidin should get an IND for Covid-19 without too much trouble. Agree with you there for sure. Hopefully LE is using some good advisors/experts/CROs to help design and run the clinical trial, and for all the FDA regulatory work. It's good to have an expert advisor and advocate like deGrado on speed dial, although more will be needed. Like who will be the Covid trial PI?
News 
Market Data 
Discover 
